Revenue during the quarter grew 1 percent to Rs 3,534.9 crore compared to Rs 3,498.5 crore a year ago.
A Reuters poll of analysts estimates an increase in net profit to Rs 358.8 crore.
Net Sales are expected to decrease by 8.5 percent Y-o-Y (up 2 percent Q-o-Q) to Rs. 2,247.6 crore, according to Edelweiss.
Net Sales are expected to decrease by 3.7 percent Y-o-Y (down 10.1 percent Q-o-Q) to Rs. 3,421.2 crore, according to Edelweiss.
Israeli is expected to steer the company out of its current slump, which is struggling with regulatory compliance issues at its plants and plummeting sales of US business
USFDA issues an EIR to an establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection.
Dr Reddy's Laboratories board has given green signal to induct Akhil Ravi, the son-in-law of GV Prasad, Co-Chairman, and CEO - of Dr Reddy's into the company management.
An official statement issued by Attorney General (AG) of Washington State, Bob Ferguson, yesterday said AGs of 45 other states, along with him, approached a federal court seeking to expand the pending complaint, increase the number of drug companies under probe to 18 from 6 and the number of affected drugs to 15 from 2.
KR Choksey recommended accumulate rating on Dr Reddy’s with a target price of Rs 2680 in its research report dated November 01, 2017.
The audit of API Mirfield plant in the UK by the US Food and Drug Administration (FDA) was completed on Friday, Dr Reddy's said in a regulatory filing to stock exchanges.
The latest jab is a part of the never-ending saga of regulatory compliance woes the company has been facing starting November 2015
The auditor has cautioned that the facility will receive EU-GMP certification for the regulator up to November 2018 only when the regulator approves CAPA.
The settlement agreement permits Dr. Reddy's to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of the generic version of Qsymia.
The drug is intended to be used for treatment of moderate to severe plaque psoriasis.
The company didn't provide any specific details of violations that led to cancellation of the GMP certificate for the plant.
Under the terms of the agreement, DRL would receive equity in CHD valued at USD 30 million upon an IPO of CHD or a minimum of USD 30 million in cash within 18 months of execution of the agreement
Drug maker Dr Reddy's Laboratories on Thursday said its net profit dropped 57 percent in the quarter ended June on account o falling sales in US and India.
Revenue is seen rising 4.6 percent year-on-year to Rs 3,383 crore in June quarter, according to average of estimates of analysts polled by CNBC-TV18.
Edelweiss' is bullish on Dr Reddys has recommended Hold rating on the stock with a target price of Rs 2660 in its research report dated July 10, 2017.
Introducing complex generics in the US and upgraded portfolio mix to help, drugmaker says.
In March 2017, the US House of Representatives passed the 'American Health Care Act' to replace the PPACA (Obamacare).
“We have been issued a Form 483 with one observation, which we are addressing,” the company said.
The plant was inspected by USFDA from February 13-21 and had received three Form 483 Observations from US FDA. Miryalaguda plant called at CTO Unit V was one among the three plants.
CNBC-TV18's Ekta Batra lists out stocks that you should focus on.